干扰素联合黄芪注射液协同防治病毒性心肌炎研究

Combined therapy and precaution for viral myocarditis

目的:探讨干扰素联合黄芪注射液协同治疗病毒性心肌炎(VM C)的临床效果及其预防价值。方法:选取本院收治的病毒性心肌炎病例240例,随机分成3组,在常规治疗的基础上分别给予干扰素、黄芪注射液和同时两者联合治疗。比较各组临床疗效,追踪其复发率的差异。结果:联合治疗组总有效率为95.0%,疗效明显优于单一治疗组(干扰素组80.0%、黄芪注射液组81.2%);且其复发率也为最低(6.3%,P<0.05)。结论:干扰素联合黄芪注射液治疗病毒性心肌炎具有协同效果,并能有效降低其复发的几率,是一项值得临床推广的综合防治措施。

ObjectiveTo explore the clinic effect of combined interferon and Astragalus injection on viral myocarditis and its preventive value. Methods 240 patients with viral myocarditis were randomly divided into 3 groups receiving interferon and Astragalus injection,respectively or simultaneously. Comparison of clinic outcome and recurrence ratio was carried out by SPSS. ResultsThe total effective rate in combined intervention group was significantly higher than that of any other group（95. 0% VS 80. 0% or 81. 2% ,P〈0. 05）,with lowest recurrence （6. 3%,P〈0. 05）. ConclusionCornbined interferon and Astragalus injection show favorable and secured clinic effect and lower recurrence on viral myocarditis.